← Search & browse all drugs
CARDIOVASCULAR SYSTEM › BETA BLOCKING AGENTS › BETA BLOCKING AGENTS › Beta blocking agents, selective
practolol
C07AB01
Forms & Strengths
- Oral tablets 100 mg
- Oral tablets 200 mg
- Intravenous injection 2 mg/mL
Adult Dosing
- Hypertension: 100 to 200 mg orally twice daily, adjusted based on response
- Angina pectoris: 100 to 200 mg orally twice daily
- Arrhythmias (acute): 5 mg IV slowly over 5 minutes, may be repeated up to a maximum of 20 mg
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Management of hypertension
- Prophylaxis and treatment of angina pectoris
- Management of cardiac arrhythmias (withdrawn from general clinical use due to severe toxicity)
Mechanism of Action
- Cardioselective beta-1 adrenergic receptor antagonist
- Decreases heart rate, myocardial contractility, and cardiac output
- Reduces renin release by the kidneys
- Possesses intrinsic sympathomimetic activity (ISA)
Contraindications
- Hypersensitivity to practolol
- Sinus bradycardia
- Second- or third-degree atrioventricular block
- Cardiogenic shock
- Decompensated heart failure
- Severe peripheral arterial disease
- History of oculomucocutaneous syndrome
Adverse Reactions
- Oculomucocutaneous syndrome (conjunctivitis, corneal scarring, skin rashes, psoriasiform eruptions, otitis)
- Bradycardia and hypotension
- Bronchospasm
- Fatigue and dizziness
- Cold extremities
- Gastrointestinal disturbances
Drug Interactions
- Calcium channel blockers (verapamil, diltiazem): increased risk of bradycardia and AV block
- Myocardial depressant anesthetics: additive negative inotropic effects
- Digitalis glycosides: increased risk of bradycardia and heart block
- Insulin and oral hypoglycemics: may mask symptoms of hypoglycemia (tachycardia, tremor)
Curated Content: Needs Vetting Before Put to Clinical Use